Where do Taysha Gene Therapies, Inc.'s ratios come from?

Every ratio is computed from Taysha Gene Therapies, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Profitability
Operating margin	-1,774.4%-644pp	-1,130.6%+488pp	-1,618.5%-458pp	-1,160.8%+64.9pp	-1,225.8%-128pp
Net margin	-1,738.4%-623pp	-1,115.3%+468pp	-1,583.7%-439pp	-1,145%+56.1pp	-1,201.1%-129pp
EBITDA margin	-1,759.7%-640pp	-1,119.6%+482pp	-1,601.3%-455pp	-1,146.2%+63.2pp	-1,209.3%-127pp
Free cash flow margin	-1,503.6%-544pp	-960.1%+390pp	-1,349.6%-330pp	-1,019.2%+144pp	-1,163.6%-184pp
Returns
Return on equity	-97.3%-28.8pp	-68.5%-3.5pp	-64.9%-13.1pp	-51.9%+107pp	-159.3%-37.4pp
Return on assets	-59.2%-15.9pp	-43.3%-3.0pp	-40.2%-5.5pp	-34.7%+24.8pp	-59.6%-5.9pp
Return on invested capital	-6,605%—	——	——	——	——
Efficiency
Asset turnover	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Liquidity
Current ratio	14×+1.8×	12.2×+1.8×	10.5×-2.0×	12.5×+7.1×	5.4×-0.1×
Quick ratio	14×+1.8×	12.2×+1.8×	10.5×-2.0×	12.5×+7.1×	5.4×-0.1×
Cash ratio	13.8×+1.7×	12×+1.7×	10.4×-2.0×	12.3×+7.2×	5.2×-0.1×
Leverage
Debt-to-equity	0.3×0.0×	0.3×0.0×	0.3×+0.1×	0.2×-0.9×	1.1×+0.2×
Debt-to-assets	0.2×0.0×	0.2×0.0×	0.2×0.0×	0.2×-0.3×	0.4×0.0×
Interest coverage	-2,501.2×-747×	-1,753.9×-355×	-1,399×-253×	-1,146.4×-184×	-962.5×-65.8×
Per Share
Book value per share	$0.58-25.2%	$0.77+24.6%	$0.62-25.7%	$0.83+308%	$0.20-28.5%
Valuation
Market capitalization	$1.28B-14.8%	$1.51B+68.9%	$892.04M+43.9%	$619.83M+118%	$284.95M-19.6%
Enterprise value	$1.08B-14.4%	$1.26B+89.4%	$663.78M+80.9%	$366.83M+59.5%	$229.99M-17.6%
Price / sales	171.9×+17.7×	154.2×+12.8×	141.4×+64.8×	76.5×+37.1×	39.4×-3.1×
Price / book	6.1×0.0×	6.1×+2.0×	4.1×+1.6×	2.5×-2.7×	5.2×+0.2×
EV / sales	144×+15.4×	128.6×+23.4×	105.2×+59.9×	45.3×+13.5×	31.8×-1.7×
Free cash flow yield	-8.7%-2.5pp	-6.2%+3.3pp	-9.5%+3.8pp	-13.3%+16.2pp	-29.5%-6.5pp
Earnings yield	-10.1%-2.9pp	-7.2%+4.0pp	-11.2%+3.8pp	-15%+15.5pp	-30.4%-5.3pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Taysha Gene Therapies, Inc.'s ratios come from?: Every ratio is computed from Taysha Gene Therapies, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.